Boehringer Ingelheim filed an application with the European Medicines Agency seeking wider approval of its oral anticoagulant Pradaxa, or dabigatran. The firm wants the drug to be approved for treatment of deep vein thrombosis and pulmonary embolism, and for the prevention of recurrent DVT and PE.

Full Story:

Related Summaries